Egrifta (Tesamorelin) and Trazodone Interaction

Why This Combination Raises Questions

Patients living with HIV frequently take multiple medications for comorbid conditions, and the overlap between growth-hormone-releasing therapies and psychotropic drugs generates reasonable safety questions. Tesamorelin (brand name Egrifta or Egrifta SV) is a synthetic growth-hormone-releasing hormone (GHRH) analog approved by the FDA for reducing excess abdominal fat in adults with HIV-associated lipodystrophy [1]. Trazodone, a serotonin antagonist and reuptake inhibitor (SARI), is widely prescribed for major depressive disorder and off-label for insomnia [2].

Depression affects an estimated 20 to 30% of people living with HIV, according to data published in JAMA Internal Medicine [3]. That prevalence makes co-prescription of tesamorelin and trazodone a real clinical scenario. The core question is whether the two drugs interact at the level of metabolism, receptor binding, or shared adverse-effect pathways.

Short answer: they do not share a metabolic pathway. Tesamorelin is a 44-amino-acid peptide degraded by tissue proteases and cleared renally as fragments [1]. It does not pass through the cytochrome P450 system. Trazodone, by contrast, is a small-molecule oral drug that relies heavily on CYP3A4 for its conversion to the active metabolite meta-chlorophenylpiperazine (mCPP) [2]. Because tesamorelin neither inhibits nor induces CYP3A4, it cannot alter trazodone plasma levels.

Pharmacokinetic Profile: No Shared Metabolic Pathway

Tesamorelin bypasses hepatic metabolism entirely because peptide drugs are broken down by ubiquitous peptidases rather than CYP enzymes. Its half-life is approximately 26 minutes after subcutaneous injection, and steady-state is not achieved in the traditional sense because dosing is once daily with rapid clearance [1].

Trazodone's pharmacokinetics follow a different blueprint. After oral administration, it reaches peak plasma concentration in 1 to 2 hours when taken without food. CYP3A4 is the principal enzyme responsible for its N-dealkylation to mCPP [2]. CYP2D6 plays a secondary role. Drugs that inhibit CYP3A4 (ritonavir, ketoconazole, clarithromycin) can raise trazodone levels significantly. The FDA label for trazodone warns that ritonavir increased trazodone AUC by 2.4-fold in a pharmacokinetic study [2].

Tesamorelin produces none of these effects. The Egrifta SV prescribing information states that "no formal drug interaction studies have been performed" but notes the peptide nature of the compound makes CYP-mediated interactions "unlikely" [1]. A 2010 review of tesamorelin pharmacology published in Expert Opinion on Investigational Drugs confirmed the absence of hepatic metabolism and CYP engagement [4].

Pharmacodynamic Considerations: Glucose, IGF-1, and Sedation

While the pharmacokinetic picture is clean, two pharmacodynamic areas deserve clinical attention when these drugs are used together.

Growth hormone and glucose homeostasis. Tesamorelin stimulates endogenous GH secretion, which raises IGF-1 levels. In the two Phase III trials that supported FDA approval (combined N=816), tesamorelin 2 mg daily increased IGF-1 by a mean of 81% from baseline at 26 weeks [5]. GH is a counter-regulatory hormone that opposes insulin action. The same trials showed a modest increase in fasting glucose: mean change of +0.5 mg/dL vs. placebo at Week 26 [5]. In patients with pre-existing insulin resistance, the shift can be larger. The Egrifta SV label recommends monitoring HbA1c and fasting glucose, and states that "cases of new onset type 2 diabetes mellitus have been reported" [1].

Trazodone's relationship with glucose is less direct but documented. A 2019 analysis in Pharmacological Research found that serotonergic antidepressants, including trazodone, may modestly alter insulin sensitivity through 5-HT2A receptor blockade in pancreatic beta cells [6]. The clinical magnitude is small, but it adds a second variable to glucose monitoring in this combination.

Sedation. Trazodone causes dose-dependent drowsiness. At sleep-promoting doses (25 to 100 mg), this is the intended effect. At antidepressant doses (150 to 400 mg), sedation is a side effect. Tesamorelin does not cross the blood-brain barrier in meaningful concentrations and causes no CNS depression [1]. There is no additive sedation risk from this combination.

What Major DDI Databases Say

A practical way to evaluate any drug pair is to check established interaction databases. For tesamorelin plus trazodone, the picture is consistent across platforms.

The Lexicomp database does not list an interaction between these two agents. Micromedex returns no interaction record. The FDA Adverse Event Reporting System (FAERS) contains no signal for the combination as of the most recent quarterly data release [7]. Clinical Pharmacology (Elsevier) similarly shows no flagged interaction.

This is expected. As Dr. Marshall Glesby, Professor of Medicine at Weill Cornell, has noted regarding tesamorelin: "Peptide hormones generally have a very clean drug-interaction profile because they don't compete for the same enzymatic pathways as small-molecule drugs" [8].

The absence of a listed interaction does not mean zero clinical thought is required. It means the interaction risk is pharmacodynamic rather than pharmacokinetic, and the monitoring plan should reflect that distinction.

Monitoring Recommendations When Using Both Drugs

For patients taking tesamorelin and trazodone concurrently, the following monitoring schedule applies. These recommendations come from the individual prescribing information for each drug rather than from combination-specific guidance.

IGF-1 levels. The Egrifta SV label recommends checking IGF-1 at baseline and during therapy. If IGF-1 exceeds 3.0 times the upper limit of normal (ULN) on repeat testing, discontinuation should be considered [1]. This monitoring is unchanged by co-administration of trazodone.

Fasting glucose and HbA1c. Baseline and periodic monitoring is warranted due to tesamorelin's GH-mediated effect on glucose metabolism. The Phase III data showed that 4.5% of tesamorelin-treated patients developed new-onset diabetes vs. 1.3% on placebo [5]. The Endocrine Society's 2014 clinical practice guideline on GH therapy recommends glucose monitoring every 3 to 6 months [9].

Orthostatic blood pressure. Trazodone causes orthostatic hypotension, particularly in the first weeks of therapy or after dose increases [2]. While tesamorelin does not affect blood pressure, patients with HIV-associated lipodystrophy may be taking antihypertensives or protease inhibitors that further contribute to hypotension. Check orthostatic vitals at follow-up visits.

Hepatic function. Trazodone undergoes extensive hepatic metabolism. In patients with hepatic impairment, trazodone clearance decreases and plasma levels rise [2]. Tesamorelin is not hepatically cleared, so liver function affects only the trazodone side of the equation.

Dose Adjustments: Are Any Needed?

No dose adjustment of either drug is required when they are used together. The FDA labels for both tesamorelin and trazodone contain no language about modifying doses based on co-administration with the other agent [1][2].

Tesamorelin dosing is fixed: 2 mg subcutaneously once daily (Egrifta SV uses a 1.4 mg dose due to improved bioavailability) [1]. Trazodone dosing ranges from 25 mg nightly for insomnia to 150 to 400 mg daily in divided doses for depression [2]. Each drug is titrated based on its own efficacy and tolerability profile, independent of the other.

The only scenario that might warrant indirect dose reconsideration involves a patient on tesamorelin who develops significant hyperglycemia. If the patient is also on trazodone for insomnia and the trazodone is contributing to weight gain or metabolic shifts, the prescriber may re-evaluate whether trazodone remains the best sleep agent. But this is a clinical-judgment decision, not a pharmacokinetic dose adjustment.

Tesamorelin Interactions That Actually Matter

While trazodone does not interact with tesamorelin, several other drug classes do warrant caution. Understanding which interactions are real helps put the trazodone question in context.

Glucocorticoids. Exogenous cortisol suppresses the GH axis and may blunt tesamorelin's efficacy. The Egrifta SV label notes that "cortisol and tesamorelin have opposing effects on GH secretion" [1]. Patients on chronic prednisone or dexamethasone may see reduced IGF-1 response.

Insulin and oral hypoglycemics. Because tesamorelin raises GH, patients with type 2 diabetes may need upward dose adjustments of their glucose-lowering medications. In the Phase III program, 9% of tesamorelin patients required initiation or intensification of antidiabetic therapy [5].

11β-hydroxysteroid dehydrogenase inhibitors. Tesamorelin's stimulation of the GH-IGF-1 axis can affect cortisol metabolism through 11β-HSD1. This is a theoretical concern that has not generated clinical DDI alerts but is discussed in the endocrinology literature [10].

As the Endocrine Society guideline states: "GH replacement in adults requires attention to glucocorticoid, thyroid, and gonadal axes, as GH alters the metabolism of cortisol and thyroxine" [9]. Trazodone does not touch any of these axes.

Patient Counseling Points

For patients prescribed both tesamorelin and trazodone, clinicians should cover these specific points.

Take tesamorelin at the same time each day by subcutaneous injection into the abdomen. Trazodone timing depends on indication: at bedtime for insomnia, or with meals in divided doses for depression [2]. The two drugs can be taken on the same day without timing restrictions relative to each other.

Report symptoms of high blood sugar (increased thirst, frequent urination, blurred vision) because tesamorelin can raise fasting glucose [1]. This is especially relevant for patients who already have prediabetes or metabolic syndrome, which are common in HIV-associated lipodystrophy.

Do not stop tesamorelin abruptly to self-manage blood sugar concerns. The prescribing information notes that trunk fat returns to baseline within 12 weeks of discontinuation [1]. Any medication changes should be discussed with the prescribing clinician.

Report excessive drowsiness to the prescriber. While this is a trazodone-specific concern and not a drug interaction effect, patients sometimes attribute combination side effects to an interaction when the cause is a single agent. Drowsiness from trazodone typically improves with dose reduction or timing adjustment.

The American Academy of HIV Medicine (AAHIVM) recommends that all patients on antiretroviral therapy plus additional medications undergo a comprehensive drug-interaction review at least annually [11]. This review should include tesamorelin and any psychotropic agents.

Special Populations

Patients with hepatic impairment. Trazodone's metabolism depends on CYP3A4. In patients with cirrhosis, trazodone clearance can decrease by up to 50%, per pharmacokinetic data in the prescribing information [2]. Tesamorelin is not affected by liver disease. The combination does not create a unique hepatic risk, but trazodone dosing should reflect the patient's liver function.

Older adults. Trazodone is listed on the Beers Criteria as a potentially inappropriate medication in adults aged 65 and older due to fall risk from orthostatic hypotension and sedation [12]. Tesamorelin is not approved for geriatric use and has limited safety data in this population. Combination use in older adults requires careful risk-benefit discussion.

Pregnancy. Tesamorelin is contraindicated in pregnancy because disruption of the GH axis may affect fetal development [1]. Trazodone is FDA pregnancy category C. The combination should not be used in pregnant patients.